PPT-Switch to LPV/r + RAL

Switch to LPVr RAL KITE Study KITE Study switch to LPVr RAL Design Age 18 years HIV No previous virologi c failure to PIrbased ART HIV1 RNA lt 50 cml On stable 6 months 2 NRTI 3rd agent. Green wire is not connected to ground Connect green wire to ground Ground is required for the sensor switch to function Models MSOPS2 MSVPS2 MSOPS5M MSVPS5M MSOPS6M2DV MSVPS6M2DV White wire is not connected to neutral Connect white wire to neutral N A and then SWITCH SIDESCCDC B Switch sides after points1,5,9,13,17, ou can temporarily switch your role Switch your role Note: Role Switch vs. Impersonate Updated: 8/18/14Page of LSCOnline Role Switch vs. Impersonate Figure 3The Role Switchwidget will reflect the M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . SWORD. . Study. Switch to CAB LA RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. stop using your credit cards - switch to MOVO to spend just what you have budgeted for the month Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. Switch to ATV/r-. containing. . regimen. ATAZIP. Switch to ATV ± r-containing . regimen. SWAN . Study. SLOAT . Study. Switch . to ATV-. containing. . regimen. ARIES . Study. INDUMA . Study. ASSURE . Reset Diet. Week 1 . Quickstart. START. First Steps. Quiz. Starting waist circumference. Starting weight. Starting AM resting heart rate. Welcome intake. Quiz Instructions. Instructions for . the . quiz:. Canadian Study. CHEER. Montreal Study. EASIER. SWITCHMRK. SPIRAL. Switch ER. Design. Endpoints. Primary: non inferiority in the proportion of patients with treatment failure at W48* (non completer = failure, intent-to-treat analysis), lower . Etraswitch. . Study. : Switch PI/r to ETR. Continuation of current . PI/R . + 2 . NRTI. N = . 21. N = . 22. ETR 400 mg QD* . + 2 NRTI. Design. Randomisation. 1: 1. Open-label. Objective. Primary . Endpoint: % HIV RNA < 50 c/mL, on-treatment and ITT, M=F. SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed . ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-TDF-FTC. ROCKET-1: Design. Source: Moyle GJ, et al. . PLoS. One. 2015;10:e0116297.. Immediate switch arm. EFV-TDF-FTC. . (n = 79). Delayed switch arm .